JoinClinicalTrials.com

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

• Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma

  NCT04046939

  Conditions:   Eosinophilic Asthma;   Asthma
  Interventions:   Drug: low-dose dexpramipexole;   Drug: mid-dose dexpramipexole;   Drug: high-dose dexpramipexole;   Drug: placebo oral tablet
  Sponsor:   Knopp Biosciences
  Recruiting
• A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause

  NCT04003389

  Condition:   Hot Flashes
  Interventions:   Drug: fezolinetant;   Drug: placebo
  Sponsor:   Astellas Pharma Global Development, Inc.
  Recruiting
• A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause

  NCT04003155

  Condition:   Hot Flashes
  Interventions:   Drug: fezolinetant;   Drug: placebo
  Sponsor:   Astellas Pharma Global Development, Inc.
  Recruiting
• Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)

  NCT03902080

  Condition:   Overactive Bladder
  Interventions:   Drug: Vibegron;   Drug: Placebo
  Sponsor:   Urovant Sciences GmbH
  Recruiting
• A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)

  NCT03843125

  Condition:   Systemic Lupus Erythematosus
  Intervention:   Drug: Baricitinib
  Sponsors:   Eli Lilly and Company;   Incyte Corporation
  Recruiting
• Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Sinusitis With or Without the Presence of Nasal Polyps

  NCT03781804

  Condition:   Chronic Sinusitis
  Intervention:   Drug: OPN-375
  Sponsor:   Optinose US Inc.
  Recruiting
• Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

  NCT03738423

  Condition:   Atopic Dermatitis
  Interventions:   Drug: REGN3500;   Drug: REGN3500-Matching Placebo
  Sponsors:   Regeneron Pharmaceuticals;   Sanofi
  Recruiting
• Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)

  NCT03712345

  Conditions:   Granulomatosis With Polyangiitis (GPA);   Microscopic Polyangiitis (MPA)
  Interventions:   Drug: IFX-1;   Drug: Placebo
  Sponsors:   InflaRx GmbH;   Iqvia Pty Ltd
  Recruiting
• Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors

  NCT03662204

  Conditions:   Breast Cancer;   Lung Cancer;   Colorectal Cancer;   Prostate Cancer;   Bladder Cancer;   Uterine Cancer;   Kidney Cancer;   Renal Pelvis Cancer;   Pancreatic Cancer;   Liver Cancer;   Stomach Cancer;   Ovarian Cancer;   Esophageal Cancer
  Intervention:   Other: Blood Sample Collection
  Sponsor:   Exact Sciences Corporation
  Recruiting
• A Study of Baricitinib in Participants With Systemic Lupus Erythematosus

  NCT03616964

  Condition:   Systemic Lupus Erythematosus
  Interventions:   Drug: Baricitinib;   Drug: Placebo
  Sponsors:   Eli Lilly and Company;   Incyte Corporation
  Recruiting
• Etokimab in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

  NCT03614923

  Condition:   Chronic Rhinosinusitis
  Interventions:   Biological: Etokimab;   Biological: Placebo
  Sponsor:   AnaptysBio, Inc.
  Recruiting
• SI-6603 (Condoliase) Study for Lumbar Disc Herniation (Discovery 6603 Study)

  NCT03607838

  Condition:   Lumbar Disc Herniation
  Interventions:   Drug: SI-6603;   Drug: Sham injection
  Sponsor:   Seikagaku Corporation
  Recruiting
• Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND

  NCT03587805

  Condition:   Atopic Dermatitis
  Intervention:   Drug: Tralokinumab
  Sponsor:   LEO Pharma
  Recruiting
• Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors

  NCT03561883

  Condition:   Gastroesophageal Reflux Disease (GERD)
  Interventions:   Drug: IW-3718;   Drug: placebo
  Sponsor:   Ironwood Pharmaceuticals, Inc.
  Recruiting
• EndoTAG-1 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment

  NCT03126435

  Conditions:   Metastatic Pancreas Cancer;   Locally Advanced Pancreatic Cancer;   Pancreatic Adenocarcinoma
  Interventions:   Drug: EndoTAG-1;   Drug: Gemcitabine
  Sponsor:   SynCore Biotechnology Co., Ltd.
  Recruiting
• Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144

  NCT02403323

  Condition:   Crohn Disease
  Intervention:   Drug: etrolizumab
  Sponsor:   Hoffmann-La Roche
  Recruiting
• A Study to Assess Whether Etrolizumab is a Safe and Effective Treatment for Participants With Moderately to Severely Active Crohn's Disease (CD)

  NCT02394028

  Condition:   Crohn Disease
  Interventions:   Drug: Etrolizumab;   Drug: Placebo
  Sponsor:   Hoffmann-La Roche
  Recruiting
• A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (Study #2)

  NCT02171429

  Condition:   Ulcerative Colitis
  Interventions:   Drug: Adalimumab;   Other: Adalimumab Placebo;   Drug: Etrolizumab;   Other: Etrolizumab Placebo
  Sponsor:   Hoffmann-La Roche
  Recruiting
• Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies

  NCT02118584

  Condition:   Ulcerative Colitis
  Intervention:   Drug: Etrolizumab
  Sponsor:   Hoffmann-La Roche
  Recruiting
• A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)

  NCT01920061

  Condition:   Neoplasm
  Interventions:   Drug: PF-05212384 (gedatolisib);   Drug: Docetaxel;   Drug: Cisplatin;   Drug: Dacomitinib
  Sponsor:   Pfizer
  Recruiting
• Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

  NCT03985943

  Condition:   Moderate-to-Severe Atopic Dermatitis
  Interventions:   Drug: Placebo;   Drug: Nemolizumab
  Sponsor:   Galderma R&D
  Recruiting
• A Phase III Study of Efficacy and Safety of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.

  NCT03580356

  Condition:   Chronic Spontaneous Urticaria
  Interventions:   Biological: Ligelizumab;   Biological: Omalizumab;   Other: Placebo
  Sponsor:   Novartis Pharmaceuticals
  Recruiting